[Antitumor activity of doxorubicin in the treatment of hemocytoblastosis La and various ascites tumors in mice]. 1984

L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg

Antitumor activity of doxorubicin made in the USSR was studied on mice in respect to three transplantable tumors (lymphadenosis NK/LI, sarcoma 37 and Ehrlich's carcinoma) and hemocytoblastosis La. Doxorubicin injected intravenously 4 times was shown to be highly active against the above ascites tumors. The highest inhibitory effect of doxorubicin was observed in respect to the development of Ehrlich's carcinoma. By the selectivity of the therapeutic effect on this tumor it was superior to rubomycin and carminomycin. A high antileukemic activity of doxorubicin in respect to hemocytoblastosis La was shown. In experiments with this leukemia, intravenous injection of doxorubicin provided a higher efficacy than intraperitoneal injection. When used intravenously in the doses equivalent by their toxicity doxorubicin was inferior to rubomycin in terms of the therapeutic effect on leukemia La. However, on intraperitoneal injection of the drugs rubomycin showed no such advantage. Doxorubicin made in the USSR did not differ by its antitumor activity from the analogous foreign drug.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D002286 Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. Ehrlich Ascites Tumor,Ascites Tumor, Ehrlich,Ehrlich Tumor Carcinoma,Tumor, Ehrlich Ascites
D002360 Carubicin A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata. Carminomycin,Karminomycin,Carminomicin,Carminomycin I,Carminomycin II,Carminomycin III,Carubicin Hydrochloride,Demethyldaunomycin,Demethyldaunorubicin,Karminomicin,NSC-180,024,NSC-180024,Rubeomycin A,Rubeomycin A1,Hydrochloride, Carubicin,NSC 180,024,NSC 180024,NSC180,024,NSC180024
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
December 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
September 2011, Journal of drug targeting,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
June 2013, Toxicology and industrial health,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
September 1960, Cancer research,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
October 2021, Journal of biochemical and molecular toxicology,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
March 1983, European journal of cancer & clinical oncology,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
April 1980, Japanese journal of pharmacology,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
January 2008, Biological & pharmaceutical bulletin,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
January 1995, Biological & pharmaceutical bulletin,
L A Ul'ianova, and V E Tarasova, and V S Bazhanov, and O I Iudina, and L E Gol'dberg
June 2012, Journal of ethnopharmacology,
Copied contents to your clipboard!